Testing a new cancer drug for advanced solid tumors
Part of Cancer, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can provide tumor biopsy samples both before starting and during treatment for lab testing
- Your cancer must have measurable tumor spots on scans that can be safely biopsied (not bone, fine-needle, or fluid-only samples)
- Your daily functioning must be fairly good (performance status 0 or 1)
- Your cancer must have gotten worse on or after your most recent treatment
- You must have already tried standard treatments, including a relevant PD-(L)1 medicine for your cancer type (if available)
- You cannot be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug for people with advanced solid tumors or lymphoma that has not responded to standard treatments and has a specific genetic change (loss of MTAP or CDKN2A genes). The drug is taken by mouth and may work by targeting cancer cells with this change.
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
This trial tests a new drug called BMS-986504 alongside standard treatments for certain advanced cancers (mesothelioma, stomach/esophageal cancer, or bladder cancer). The drug targets a specific genetic change (MTAP deletion) that may make cancer cells more vulnerable to treatment. Joining could help you access a new therapy, but it may not be suitable for everyone.
This trial is testing a new drug (BMS-986517) for people with advanced solid tumors, including certain lung, head and neck, and breast cancers. The goal is to see if the drug is safe and effective.
This trial tests a new investigational drug, BMS-986488, alone or with another drug (adagrasib), for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and works against certain cancers.
This trial tests an investigational drug (BMS-986463) in people with advanced solid tumors. It aims to find a safe dose and see if it helps shrink or control the cancer. You must be well enough to do daily activities and have a tumor that can be biopsied before treatment starts.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.